Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese fund GIBF2. This brings the total funds raised by Kamari to $16 million. The company was established at the end of 2018 by leading Israel-based biotech funds Pontifax and Arkin Bioholdings. Kamari develops topical and oral drugs based on proprietary small molecules that inhibit the TRPV3 ion channel, focusing on severe genetic skin disorders such as keratoderma and Lichen Simplex Chronicus.
Investment Details and Fund Background
GIBF2 is the second fund raised by the Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF), with $300 million accrued to target investments into Chinese-Israeli joint ventures (JVs) in the biomedical field, as announced in June last year. The investment in Kamari marks a significant step in fostering collaboration and innovation between Chinese and Israeli biotech companies.
Future Outlook
The funding from GIBF2 will support Kamari Pharma’s ongoing research and development efforts, particularly in advancing its TRPV3 inhibitor drugs. With a focus on severe genetic skin disorders, Kamari aims to address significant unmet needs in dermatology through its innovative therapeutic approaches.-Fineline Info & Tech
